Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aproCltentan in Subjects with Resistant Hypertension (RHT)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: IDORSIA PHARMACEUTICALS LTD
- Phase: III
- Execution start: 25/06/2020
- End of execution: 30/03/2022
- PI: JUAN DIEGO MEDIAVILLA GARCIA